Gayatri BioOrganics Limited has accepted the resignation of Venkata Sandeep Kumar Reddy Tikkavarapu from his positions as Chairman and Non-Executive Director. The resignation takes effect on August 5, 2026, following a letter dated August 4, 2026, in which Reddy cited professional responsibilities and personal reasons for stepping down. This leadership change impacts the governance structure of the Hyderabad-based agri-inputs company, requiring the Board to address the vacancy in its upcoming proceedings.

The resignation also covers Reddy’s membership in all board committees. In his resignation letter, Reddy requested that the company acknowledge receipt and submit the necessary forms to the office of the Registrar of Companies (ROC) and the relevant Stock Exchanges to formalize the change. The Board of Directors has confirmed acceptance of these terms.

Key Details of Resignation

Venkata Sandeep Kumar Reddy Tikkavarapu holds DIN 00005573. His departure marks a significant shift in the company’s senior management team. The company is expected to initiate the process of appointing a new Chairman and potentially other directors to fill the resulting vacancies in accordance with regulatory requirements.

Governance Implications

The resignation necessitates immediate attention from the Board regarding succession planning. As the outgoing Chairman, Reddy’s exit may influence ongoing strategic initiatives and committee-level oversight until a successor is appointed. The company must ensure compliance with listing regulations concerning the timely disclosure of such changes and the filing of requisite forms with market regulators.

No financial metrics were disclosed in relation to this personnel change. The focus remains on the procedural aspects of the transition and the subsequent steps required to maintain effective corporate governance at Gayatri BioOrganics Limited.

Gayatri BioOrganics Limited reported a net loss of ₹10.17 lakh for the quarter ended June 30, 2026, narrowing significantly from the ₹26.29 lakh loss recorded in the same period of FY25. Revenue from operations for Q1FY26 was ₹233.66 lakh. Alongside the financial results, the Board of Directors approved a proposal to change the company’s name to Ananth BioOrganics Limited or similar variants, subject to regulatory approvals. Additionally, Sreedhara Reddy Kanaparthi was appointed as Chairman and Managing Director effective August 5, 2026, succeeding Venkata Sandeep Kumar Reddy Tikkavarapu, who resigned due to professional responsibilities.

The Board meeting, held on August 4, 2026, in Hyderabad, also reviewed the unaudited financial results and the limited review report by MGR & Co, Chartered Accountants. The company announced its 35th Annual General Meeting (AGM) scheduled for September 23, 2026, to be conducted via video conference or other audio-visual means (OAVM). The Board further approved the adoption of new Memorandum of Association (MOA) and Articles of Association (AOA) to align with the Companies Act, 2013, pending member approval.

Financial Performance

The company’s total income for the quarter was ₹233.66 lakh, driven entirely by revenue from operations. Total expenses amounted to ₹243.84 lakh, comprising ₹215.45 lakh for purchase of stock-in-trade, ₹15.60 lakh in other expenses, ₹10.68 lakh in finance costs, and ₹2.11 lakh in employee benefits expenses.

For the full year ended March 31, 2026, the company reported a net loss of ₹111.18 lakh on total expenses of ₹111.18 lakh. The paid-up equity share capital remains at ₹7,878.81 lakh. The financial statements were prepared on a going concern basis, supported by a comfort letter from the promoters regarding future business continuity.

Leadership Transition

Venkata Sandeep Kumar Reddy Tikkavarapu resigned as Chairman and Non-Executive Director effective August 5, 2026. He holds 1,70,06,802 shares in the company. Sreedhara Reddy Kanaparthi, previously the Whole-time Director, has been designated as Chairman and Managing Director for a three-year term, subject to member approval. Kanaparthi brings over two decades of experience in leveraging technology for human welfare and holds an MBA from 1999–2001. He confirmed no relationships with other directors and is not debarred by SEBI or any other authority.

What the Numbers Show

The reduction in quarterly net loss from ₹26.29 lakh in Q1FY25 to ₹10.17 lakh in Q1FY26 indicates improved operational efficiency despite continued losses. Total expenses in Q1FY26 were ₹243.84 lakh against revenue of ₹233.66 lakh, suggesting that while the company remains unprofitable, the gap between income and expenditure has narrowed considerably compared to the prior year period where expenses were lower but revenue data was not disclosed in the comparative column. The consistent negative net worth of ₹3,700.49 lakh at the end of FY26 highlights ongoing capital challenges, necessitating the promoter support cited in the going concern note.